Minnesota’s adult obesity rate has dropped for the second year in a row, sparking debate over whether new GLP-1 weight-loss medications or longer-term public-health efforts are driving the decline. Data from the federal Behavioral Risk Factor Surveillance System show that just over 32% of Minnesota adults were obese in 2024, down from nearly 34% in 2022, coinciding with a dramatic surge in prescriptions for drugs like Ozempic, Wegovy, and Zepbound.
Medicaid Spending On GLP-1s Soars
Minnesota’s Medicaid program saw gross spending on GLP-1 medications jump from roughly $20 million in 2019 to about $133 million in 2024, according to reporting by the Star Tribune. However, state survey leaders cautioned that a two-year dip remains within the survey’s margin of error, making it difficult to establish direct cause-and-effect relationships between the drugs and the obesity decline.
Access And Coverage Remain Fragmented
Coverage of GLP-1s for obesity varies widely by insurer and state. A KFF analysis shows that most states covering the drugs use utilization controls such as prior authorization and BMI thresholds. These restrictions mean some Minnesotans receive coverage while others face full retail prices, with uninsured patients sometimes paying four-figure monthly bills despite available discounts and rebate programs.
Long-Term Effectiveness Still Uncertain
Clinical trials demonstrate large short-term weight loss with GLP-1 medications, but long-term outcomes remain murky. The American Diabetes Association reports that “sudden discontinuation … results in weight recurrence of one-half to two-thirds of the weight loss within 1 year” and recommends close follow-up and shared decision-making around sustained therapy. Researchers emphasize the need for more real-world data to determine whether these drugs will drive down chronic-disease rates across entire populations.
Real-world experiences vary widely. One Minnesotan lost about 65 pounds and lowered her diabetes risk after starting injections, while another quit after two months due to nausea and appetite loss. Harvard Health identifies nausea, vomiting, and diarrhea as common reasons people discontinue treatment.
Public-health leaders stress that prevention programs—including SHIP grants supporting walking paths and community nutrition initiatives—remain essential to any long-term obesity reduction strategy. The Minnesota Department of Health continues supporting local investments alongside clinical care, with state policy decisions about medication funding versus broad prevention efforts likely to shape whether current gains prove lasting.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://hoodline.com/2026/03/slimmer-minnesota-obesity-slips-as-glp-1-shots-surge/